BioSpace News Archive

Celltrion agreed Wednesday to jointly develop Abpro’s cancer molecule ABP-102 in a deal that could net as much as $1.75 billion. See inside for more cancer collaborations.

This week’s money flowed into various therapeutic areas like cancer and inflammatory disorders, while government and philanthropic grants fund the fight against infectious diseases.

Poxel presented positive histology data from its Phase II DESTINY-1 trial in non-alcoholic steatohepatitis (NASH), with its primary efficacy endpoint of liver fat decrease at 36 weeks.

A 3-judge panel questioned the legitimacy of Johnson & Johnson’s plan to form a subsidiary company with the purpose of absorbing legal liabilities from talc-related lawsuits.

After enduring nine months of clinical holds, Merck announced that it is restarting the Phase III clinical program for islatravir, its candidate for people with HIV-1 infection.

Novo Nordisk and Octagon Therapeutics announced that they forged a research collaboration focused on inflammatory diseases.

Carisma Therapeutics is merging with Sesen Bio to advance Carisma’s cell therapy platform - in particular, its chimeric antigen receptor macrophage (CAR-M) therapies.

In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the submission of a Biologics License Application to the U.S. Food and Drug Administration for SC efgartigimod for the treatment of generalized myasthenia gravis in adult patients.

Axion BioSystems announces Maestro TrayZ, an innovative, live-cell analysis platform designed for high-throughput drug development and therapeutic discovery.